Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab
Cancers · 02.03.2026 · 18 (5) · 805
DOI: 10.3390/cancers18050805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.03.2026. Verfasst von Kaja Michalczyk und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
With an ongoing debate concerning the optimal timing of advanced ovarian cancer surgical treatment, primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (IDS), this study aimed to compare survival outcomes between PDS and IDS populations and evaluate prognostic factors in a real-world cohort of patients treated with first-line chemotherapy and bevacizumab.
Methods
A retrospective multi-center study was conducted involving 369 patients with newly diagnosed advanced ovarian cancer. Patient data included demographics, histology, treatment details, chemotherapy response, and survival outcomes. Kaplan–Meier estimates with log-rank tests were used for univariate analyses, as well as Cox proportional hazard models for multivariate analyses.
Results
Patients undergoing IDS were older (62.5 vs. 60.0 years), had higher pretreatment CA-125 (1846 vs. 395.6 IU/mL), an increased proportion were at with stage IV (36.25% vs. 21.10%), and they received fewer bevacizumab cycles (12 vs. 18) compared to those undergoing PDS. Median progression-free survival (PFS) was 18.6 months (95% CI: 17.3–20.2) and overall survival (OS) was 45.4 months (95% CI: 41.1–52.1). Multivariate analysis confirmed poor chemotherapy response (HR 1.80, 95% CI: 1.36–2.37; p < 0.0001) and IDS (HR 1.65, 95% CI: 1.37–2.39; p < 0.0001) as independent predictors of shorter PFS. For OS, independent risk factors were age > 70 (HR 1.62; p = 0.0202), poor response (HR 2.03; p < 0.0001), and IDS (HR 1.75; p = 0.0006).
Conclusions
In this real-world cohort treated with first-line chemotherapy and bevacizumab, interval debulking surgery was associated with inferior progression-free and overall survival compared with primary debulking surgery. However, these findings reflect a high-risk population and are strongly influenced by patient selection and treatment pathways, underscoring the need for cautious interpretation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland.
- Department of Clinical Oncology and Radiotherapy, St. John Paul 2nd Mazovia Regional Hospital in Siedlce, 08-110 Siedlce, Poland.
- Faculty of Medical and Health Sciences, University of Siedlce, 08-110 Siedlce, Poland.
- Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland.
- Second Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Gynaecological Oncology, Maria Sklodowska-Curie Bialystok Oncology Centre, 15-027 Bialystok, Poland.
ORCID-Profile: Kaja Michalczyk, Lubomir Bodnar, Paweł Derlatka, Wioleta Sawczuk, Szymon Piątek, Ewa Kalinka
Zitieren
APA
Michalczyk, K., Bodnar, L., Czeluścińska-Murawiec, M., Dańska-Bidzińska, A., Derlatka, P., Maćkowiak-Matejczyk, B., Sawczuk, W., Radecka, B., Operacz, E., Piątek, S., Kalinka, E., Miller, A., & Chudecka-Głaz, A. (2026). Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab. Cancers, 18(5), 805. https://doi.org/10.3390/cancers18050805
Vancouver
Michalczyk K, Bodnar L, Czeluścińska-Murawiec M, Dańska-Bidzińska A, Derlatka P, Maćkowiak-Matejczyk B, et al. Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab. Cancers. 2026;18(5):805. doi:10.3390/cancers18050805
BibTeX
@article{Michalczyk2026,
author = {Michalczyk, Kaja and Bodnar, Lubomir and Czeluścińska-Murawiec, Marta and Dańska-Bidzińska, Anna and Derlatka, Paweł and Maćkowiak-Matejczyk, Beata and Sawczuk, Wioleta and Radecka, Barbara and Operacz, Edyta and Piątek, Szymon and Kalinka, Ewa and Miller, Adam and Chudecka-Głaz, Anita},
title = {Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab},
journal = {Cancers},
year = {2026},
volume = {18},
number = {5},
pages = {805},
doi = {10.3390/cancers18050805}
}
EUVIMED